We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on ...

In trading on Wednesday, shares of BridgeBio Pharma Inc (Symbol: BBIO) crossed below their 200 day moving average of $28.50, changing hands as low as $28.32 per share. BridgeBio Pharma Inc shares ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Pharma presented results showing statistically significant improvements in clinical outcomes as compared to placebo for time ...

Redburn Atlantic initiated coverage of BridgeBio with a Buy rating and $50 price target Therapeutic options for patients with transthyretin ...

BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases, today ...

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...